Clinical trials: PTSD - Post Traumatic Stress Disorder
- Condition PTSD - Post Traumatic Stress Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
PTSD
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD.
- Trial name
- MPVA6 (NCT04784143)
- Testing
- Midomafetamine, Psychotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.
- Trial name
- MAPPUSX (NCT04714359)
- Testing
- Midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT03282123
- Testing
- Midomafetamine, Manualized therapy
- Where
- 12 sites in United States
- Volunteers
- 38 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition.
- Trial name
- P202 (NCT02421679)
- Testing
- TNX-102 SL
- Where
- 22 sites in United States
- Volunteers
- 159 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD.
- Trial name
- NCT03110575
- Testing
- TNX-102 SL
- Where
- 32 sites in United States
- Volunteers
- 190 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine.
- Trial name
- RECOVERY (NCT03841773)
- Testing
- TNX-102 SL
- Where
- 30 sites in United States
- Volunteers
- 192 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label…
- Trial name
- P306 (NCT03508700)
- Testing
- TNX-102 SL 5.6 mg
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT04030169
- Testing
- Midomafetamine HCl
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 21 people
- Sponsor
- MAPS Europe B.V.
PTSD
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine.
- Trial name
- AtEase (NCT02277704)
- Testing
- TNX-102 SL
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine.
- Trial name
- HONOR (NCT03062540)
- Testing
- TNX-102 SL
- Where
- 44 sites in United States
- Volunteers
- 358 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD).
- Trial name
- NCT01339689
- Testing
- Ganaxolone
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Marinus Pharmaceuticals
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Obstructive Sleep Apnea (OSA), Post-Traumatic Stress Disorder (PTSD)
Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD
The purpose of this research is to examine the application of AutoCPAP with and without SensAwake in subjects with OSA and Post-Traumatic Stress Disorder (PTSD), and evaluate whether patients achieve better sleep quality and…
- Trial name
- NCT02549508
- Testing
- AutoCPAP with SensAwake On, AutoCPAP with SensAwake Off
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Fisher and Paykel Healthcare
Post-traumatic Stress Disorder, PTSD
Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.
- Trial name
- NCT01987960
- Testing
- Brexpiprazole
- Where
- 59 sites in United States, Estonia and 7 more
- Volunteers
- 417 people
- Sponsor
- H. Lundbeck A/S